Buy these small-cap stocks set for big gains in the spring, says Oppenheimer

Oppenheimer listed 30 small- and mid-cap stocks (market caps $1B–$12B) as outperform candidates that could rally into spring. Alumis has more than doubled YTD and carries a $55 price target implying ~150% upside from Tuesday's close after positive pivotal trial data for envudeucitinib. Nurix is down ~18% YTD but has a $28 target (~80% upside), and DigitalOcean has a $100 target (~>16% upside) driven by improving customer traction and AI inferencing demand.

Analysis

Small- and mid-cap winners in healthcare and cloud are generating disproportionate flows that can accelerate both momentum and M&A dynamics. When a small biotech demonstrates clinical differentiation, the near-term effect is re-rating via reallocated active flows and multiple expansion, while the 6–24 month second-order effect is increased licensing interest from large pharmas and outsized demand for CDMO capacity that tightens timelines and raises COGS for peers.

On the cloud/AI side, low-cost providers that win early SMB inferencing workloads can scale ARPU through adjacent managed services, but scaling AI inference at price points below hyperscalers requires a meaningful capex pivot (accelerators, networking) — if they underinvest they lose share, if they overinvest they dilute margins and may need equity raises within 12–18 months. Incumbent hyperscalers face margin compression in low-end segments, which creates a durable two-tier market: hyperscalers for enterprise AI and nimble specialists for developer/SMB use-cases.

Key risks are classic for small-caps: binary clinical readouts, dilution from follow-on financings, and execution risk on infrastructure rollouts. Time horizons differ: positive trial news and partnership chatter move biotech names within weeks–months; cloud execution and capex cadence play out over 6–24 months. A contrarian read is that current momentum has already priced near-term positive outcomes; downside is asymmetric if several names hit negative catalysts simultaneously, compressing investor sentiment and liquidity across the small-cap segment.

Key Decisions for Investors

• Long NRIX (1–1.5% NAV) through a 6–12 month window into expected clinical and partnership cadence; protect with 3–6 month 20–25% OTM puts or equivalent put spread. Rationale: binary upside from successful readouts/partnering (potential >2x) vs defined downside limited by protective puts (loss capped ~25–40%).
• Long DOCN via a 12-month call spread sized ~1.5% NAV equivalent (buy nearer-term ATM calls funded by selling higher-strike calls) to express SMB AI inferencing adoption while capping capex downside. Timeframe 9–18 months; reward asymmetric if ARPU expansion materializes, risk limited to premium paid (target R/R ~3:1 if thesis executes).
• Pair trade: Long OPY (1% NAV) vs short BMY (0.5% NAV) over 3–9 months to express small-cap product momentum outpacing legacy incumbent share in niche pockets. Use a 20% stop on the long leg and a 30% stop on the short; upside if small-cap re-rating persists or if incumbent faces pricing/volume pressure, downside if macro hurts small-cap liquidity.
• Portfolio hedge: Buy a 3–6 month small-cap healthcare put spread sized 0.5% NAV to protect against clustered negative clinical outcomes and follow-on dilution risk. This keeps tail insurance costs contained while offering meaningful payback if multiple adverse catalysts hit the sector simultaneously.